Suven Life Sciences secures product patents in four countries

04 Apr 2019 Evaluate

Suven Life Sciences has been granted one product patent from Israel, one product patent from Japan, one product patent from New Zealand and one product patent from Sri Lanka corresponding to the New Chemical Entities for the treatment of disorders associated with Neurodegenerative diseases and patents are valid through 2036 and 2029 respectively.

The granted claims of the patents include the class of selective 5-HT4 and M1 PAM compounds and are being developed as therapeutic agents for neurodegenerative disorders such as for the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer's disease, Attention deficient hyperactivity disorder (ADHD), Huntington's disease, Pain, Parkinson Disease and Schizophrenia etc.

Suven Life Science is a biopharmaceutical company focused on discovering, developing and commercializing novel pharmaceutical products, which are first in class or best in class CNS therapies using GPCR targets.

Suven Life Sciences Share Price

173.70 1.75 (1.02%)
17-Dec-2025 09:27 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1779.45
Dr. Reddys Lab 1273.40
Cipla 1498.50
Zydus Lifesciences 920.00
Lupin 2118.85
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×